Table 1.
Main characteristics of ovarian cancer patients and corresponding tumor cell lines.
| ID | Age | Mutated germline BRCA | Stage at diagnosis | Histology | Tumor grade | Number of previous lines of chemotherapy | Chemotherapic agents employed |
|---|---|---|---|---|---|---|---|
| pdOVC 02 | 73 | BRCA 1 mutated | IV | serous | G3 | 2 | carboplatin, paclitaxel |
| pdOVC 03 | 69 | unknown | IV | serous | G3 | 2 | cisplatin, PLD |
| pdOVC 04 | 61 | unknown | IIIc | serous | G3 | 2 | carboplatin, paclitaxel |
| pdOVC 05 | 45 | unknown | IIIc | serous | G3 | 3 | carboplatin, paclitaxel, bevacizumab, trabectedin, gemcitabine |
| pdOVC 06 | 53 | unknown | IIIc | serous | G1 | 1 | carboplatin, paclitaxel |
| pdOVC 07 | 56 | BRCA 2 mutated | IIIc | serous | G3 | 0 | na |
| pdOVC 08 | 67 | unknown | unknown | serous | borderline | 2 | carboplatin, paclitaxel |
| pdOVC 12 | 43 | BRCA 1 mutated | IIIc | serous | G3 | 0 | na |
| pdOVC 14 | 52 | unknown | IV | serous | G3 | 0 | na |
Abbreviations: na: not applicable.